Medicare is expected to announce a decision on Transcatheter Aortic Valve Replacement (TAVR) coverage, which could impact millions of seniors. For 14 years, TAVR access has been restricted under a Coverage with Evidence Development (CED) requirement, limiting its use to clinical trials and specific hospitals. Professional societies like the Society for Thoracic Surgeons and American College of Cardiology have reportedly influenced these restrictive policies, potentially beyond clinical concerns, as the procedure represents a significant shift in heart valve treatment and revenue streams for specialists. AI
RANK_REASON The article discusses a significant policy decision by a major government agency (Medicare) that will affect millions of people and involves the influence of professional societies on that policy. [lever_c_demoted from significant: ic=1 ai=0.1]
- American College of Cardiology
- Centers for Medicare & Medicaid Services
- Joe Grogan
- Medicare
- Society for Thoracic Surgeons
- Transcatheter Aortic Valve Replacement
- Trump
- USC Schaeffer Institute
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
